- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA grants priority review to possible treatment for DR
The Food and Drug Administration (FDA) granted priority reviewstatus to Eli Lilly & Co.'s ruboxistaurin mesylate (proposedbrand name Arxxant), a possible treatment for diabetic retinopathy(DR).
The FDA granted priority review status to Eli Lilly & Co.'s ruboxistaurin mesylate (proposed brand name Arxxant), a possible treatment for diabetic retinopathy (DR).
In a phase III clinical trial, ruboxistaurin significantly reduced the occurrence of sustained moderate visual loss in patients being treated for moderate-to-very-severe DR. The 3-year trial involved 685 patients.
More than 2,000 patients have been treated with ruboxistaurin in clinical trials. Some patients have taken the drug for up to 4 years. No significant safety issues have been identified in any of the clinical trials.
